Effectiveness of school-based preventive chemotherapy strategies for sustaining the control of schistosomiasis in Côte d'Ivoire: Results of a 5-year cluster randomized trial

Mamadou Ouattara¹,²*, Nana R. Diakité¹,², Patrick K. Yao¹, Jasmina Saric³,⁴, Jean T. Coulibaly¹,²,³,⁴, Rufin K. Assaré¹,²,³,⁴, Fidèle K. Bassa¹,², Naférima Koné¹, Négnerogo Guindo-Coulibaly¹, Jan Hattendorf³,⁴, Jürg Utzinger³,⁴, Eliézer K. N’Goran¹,²

¹ Unité de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d’Ivoire, 2 Centre Suisse de Recherches Scientifiques en Côte d’Ivoire, Abidjan, Côte d’Ivoire, 3 Swiss Tropical and Public Health Institute, Basel, Switzerland, 4 University of Basel, Basel, Switzerland

* mamadou_ouatt@yahoo.fr

Abstract

Background
Preventive chemotherapy using praziquantel is the mainstay for schistosomiasis control. However, there is little evidence on what is supposed to be the most effective school-based treatment strategy to sustain morbidity control. The aim of this study was to compare differences in *Schistosoma mansoni* prevalence and infection intensity between three different schedules of school-based preventive chemotherapy in an area with moderate prevalence of *S. mansoni* in Côte d’Ivoire.

Methodology
Seventy-five schools were randomly assigned to one of three intervention arms: (i) annual school-based preventive chemotherapy with praziquantel (40 mg/kg) over four years; (ii) praziquantel treatment only in the first two years, followed by two years without treatment; and (iii) praziquantel treatment in years 1 and 3 without treatment in-between. Cross-sectional parasitologic surveys were carried out prior to each round of preventive chemotherapy. The difference in *S. mansoni* prevalence and infection intensity was assessed by multiple Kato-Katz thick smears, among children aged 9–12 years at the time of each survey. First-grade children, aged 5–8 years who had never received praziquantel, were also tested at baseline and at the end of the study.

Principal findings
Overall, 7,410 children aged 9–12 years were examined at baseline and 7,223 at the final survey. The baseline prevalence of *S. mansoni* was 17.4%, 20.2%, and 25.2% in arms 1, 2, and 3, respectively. In the final year, we observed the lowest prevalence of 10.4% in arm 1, compared to 18.2% in arm 2 and 17.5% in arm 3. The comparison between arms 1 and 2...
estimated an odds ratio (OR) of 0.52 but the difference was not statistically significant (95% confidence interval (CI) = 0.23–1.16). Likewise the difference between arms 1 and 3 lacked statistical significance (OR = 0.55, 95% CI = 0.23–1.29). There was no noteworthy difference observed between arms 2 and 3 (OR = 1.06, 95% CI = 0.64–1.75). The lowest $S. \text{mansoni}$ fecal egg counts in the final year survey were observed in arm 1 (7.9 eggs per gram of stool (EPG)). However, compared with 11.5 EPG in arm 2 and 15.4 EPG in arm 3, the difference lacked statistical significance. There were 4,812 first-grade children examined at baseline and 4,513 in the final survey. The overall prevalence of $S. \text{mansoni}$ in these children slightly decreased in arms 1 (from 4.5% to 3.6%) and 2 (from 4.7% to 4.3%), but increased in arm 3 (from 6.8% to 7.9%). However, there was no significant difference in prevalence and infection intensity observed between study arms.

Conclusions/significance

The three treatment schedules investigated led to a reduction in the prevalence and intensity of $S. \text{mansoni}$ infection among children aged 9–12 years. Comparing intervention arms at the end of the study, no statistically significant differences were observed between annual treatment and the other two treatment schedules, neither in reduction of prevalence nor intensity of infection. It is important to combine our results with those of three sister trials conducted simultaneously in other African countries, before final recommendations can be drawn.

Author summary

The World Health Organization (WHO) recommends preventive chemotherapy with praziquantel as the global strategy for morbidity control of schistosomiasis. The guidelines include target groups and treatment frequencies based on prevalence in school-age children. However, these recommendations are based on expert opinion. The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) put forward a series of cluster-randomized trials in different African countries, including Côte d’Ivoire, to identify the most suitable approach to gain and sustain the control of schistosomiasis. Results from Côte d’Ivoire did not show statistically significant differences between three school-based treatment schedules (i.e., annual treatment over four years; treatment only in the first two years, followed by two years without treatment; and treatment every other year without treatment in-between) in reducing prevalence and intensity of $Schistosoma mansoni$ infection among children aged 9–12 years. The results in first-grade children with an age of 5–8 years entering school who had never received deworming drugs showed no significant difference in the prevalence and intensity of $S. \text{mansoni}$ infection between the different treatments at the study end, suggesting that the three strategies were not significantly different for reducing the disease transmission in affected communities. However, our data should be combined with other SCORE studies carried out elsewhere in Africa. A meta-analysis including the results of the sister trials could help to conclude and make more generic recommendations.
Introduction

Schistosomiasis is a neglected tropical disease (NTD) that remains endemic in sub-Saharan Africa, where it causes a considerable public health burden [1–3]. With the advent of the safe, efficacious, and broad-spectrum antischistosomal drug praziquantel in the late 1970s, the World Health Organization (WHO) endorsed morbidity control as the global strategy [4]. The NTD roadmap, published by WHO in 2012, set targets for 2020, emphasizing preventive chemotherapy, which is the periodic administration of praziquantel to school-age children and other high-risk groups without prior diagnosis [5]. In 2016, 70.9 million school-age children requiring preventive chemotherapy received praziquantel, owing to an estimated coverage of 53.7% [6].

In Côte d’Ivoire, the national schistosomiasis control program was launched in 2012, supported by the Schistosomiasis Control Initiative (SCI). In order to identify the most effective strategy for preventive chemotherapy, taking into consideration operational feasibility and costs, the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) designed a series of cluster-randomized trials, implemented in several African countries, including Côte d’Ivoire [7–9].

In view of current recommendations for preventive chemotherapy that are largely based on expert opinion, the goal of this study was to generate new evidence about the effectiveness of different school-based treatment strategies for controlling *Schistosoma mansoni* infection. Three school-based treatment strategies were compared in a setting of moderate endemicity, defined as prevalence of infection of 10–24% among children aged 13–14 years, based on duplicate Kato-Katz thick smears. The study endorsed a cluster-randomized design. The primary objective was to assess the difference in prevalence and intensity of *S. mansoni* infection between study arms at the final survey with a view to determine which strategy of mass drug administration (MDA) provided the greatest reduction in these indicators in children aged 9–12 years. A secondary objective was to assess the infection prevalence and intensity of first-grade children, aged 5–8 years, in the same population, who entered school and had never received praziquantel, at baseline and at the final survey. This allowed to determine the degree of transmission during the study. Our study complements SCORE trials carried out elsewhere in sub-Saharan Africa [10–12].

Methods

Ethics statement

Ethics approval was obtained from the Ministry of Public Health in Côte d’Ivoire (reference no. 1994 MSHP/CNER) and from the Ethics Committee of Basel, Switzerland (reference no. EKBB 279/10). The trial is registered at ISRCTN (reference no. ISRCTN99401114). Local authorities, school directors, teachers, parents, guardians, and children in the study villages were informed about the purpose, procedures, and potential risks and benefits of the study. Parents and guardians of study participants provided written informed consent, while children were assenting. Participation was voluntary, and hence, children could withdraw anytime without further obligations.

Study area and population

The 75 study villages are located in four regions in the western part of Côte d’Ivoire: Cavally, Guémon, Haut-Sassandra, and Tonkpi (Fig 1). This mountainous region with altitudes ranging from 300 m to over 1,000 m above sea level featuring several rivers is known to be endemic for *S. mansoni*. The climate is humid tropical with a rainy season from March to October and
Fig 1. Study area in western Côte d’Ivoire showing the 75 villages, stratified by intervention arms. Arm 1: praziquantel treatment every year; Arm 2: praziquantel treatment only in the first two years, followed by two years without treatment; Arm 3: praziquantel treatment every other year without treatment in-between.

https://doi.org/10.1371/journal.pntd.0008845.g001
precipitation varying from 1,200 mm to 2,000 mm per year. The last census of the population in this area, prior to the start of the current study, was conducted in 1998 and revealed approximately 1.5 million inhabitants. The main economic activity in western Côte d’Ivoire is subsistence agriculture [13]. For water supply and other domestic activities, people use rain water, rivers, traditional wells, creeks, fountains, small multi-purpose dams, ponds, tap water, and spring water [14]. Some domestic (e.g., washing dishes and clothes), economic (e.g., fishing), and recreational activities of the communities (e.g., bathing and swimming), are associated with human-water contacts that govern schistosomiasis transmission [15]. School-age children from this region constitute our study population. Of note, this age group is widely recognized as the most exposed to schistosomiasis. In each village, prevalence and intensity of *S. mansoni* infection were determined among pupils at school, while all school-age children, whether pupils or not, were taken into account in preventive chemotherapy. Details of the study area and population surveyed have been described elsewhere [16,17].

**Study design and interventions**

The study design was a cluster-randomized trial with three parallel arms of 25 villages each. The reason for adopting such a study design was justified on village-level infection dynamics and the fact that preventive chemotherapy is usually school-based. Overall, 75 primary schools were selected and allocated to one of the three arms, using a computer generated block randomized allocation sequence. Each arm was assigned to one particular treatment strategy for a 4-year period. According to the protocol, school-age children in villages of arm 1 received praziquantel treatment every year. Those in villages of arm 2 received treatment only in the first 2 years, followed by two years without treatment. Children in villages of arm 3 were treated every other year with no treatment in-between.

Treatment was done through the existing education platform. In a first step, a baseline survey was conducted in each of the 75 villages, followed by four years of interventions according to the different intervention arms. A few days before each assigned treatment, a parasitologic survey was carried out in the study villages among 9- to 12-year-old children. First-grade children, aged 5–8 years, were also tested at baseline and during the final-year survey. The final data collection was implemented in all villages at the end of the 4-year intervention period.

**Eligibility criteria**

The selection of study villages has been described elsewhere [9]. In brief, villages were selected for eligibility according to the following criteria: (i) each village has a primary school with at least 100 children aged 9–12 years (determined by readily available school lists); (ii) no recent (within the past 12 months) history of MDA using praziquantel against schistosomiasis, as determined by a questionnaire distributed to health and education personnel; and (iii) prevalence of *S. mansoni* ranging between 10% and 24% among a random sample of 50 children aged 13–14 years, as determined by duplicate Kato-Katz thick smears from a single stool sample examined in a rapid appraisal survey.

After a village was deemed eligible, all school-age children, regardless of whether or not they attended school, were included for preventive chemotherapy. However, for parasitologic surveys, only children enrolled in school were included. Children aged 9–12 years with written informed consent signed by parents or guardians in addition to having given oral assent, were randomly selected. At the baseline and final surveys, a sample of first-grade children aged 5–8 years, randomly selected based on the aforementioned eligibility criteria, was included in addition to the 9–12 years age-group in each study arm.
Parasitologic survey

In each school, 100 randomly selected children aged 9–12 years fulfilling inclusion criteria were provided with empty plastic containers (125 ml). Every morning during three consecutive days, children were invited to provide a small portion of their morning stool in containers. Filled containers were collected, labelled with unique identifiers, and transferred to nearby laboratories in dispensaries and hospitals for diagnostic work-up. Every stool sample was subjected to duplicate Kato-Katz thick smears, using 41.7 mg plastic templates, making two series of slides (A and B) [18]. During the baseline and final surveys, we also recruited up to 100 first-grade children aged 5–8 years per school.

For diagnosis, slides of set A were examined under a microscope by experienced laboratory technicians after a clearing time of 30–45 min. This diagnostic approach provided an opportunity to identify and count hookworm eggs before they cleared and disappeared, along with counting S. mansoni and other helminth eggs that were recorded separately. Slides of set B were examined a few days later. Approximately 10% of the slides were re-examined by a senior technician for quality control, putting emphasis on S. mansoni. In case of discrepancies, the slides were re-read until agreement was reached [19,20].

School-based treatment strategies

Praziquantel was provided by SCI to the national schistosomiasis control program in Côte d’Ivoire, which carried out the preventive chemotherapy supported by staff of the national school health program. First, the regional health authorities were informed about the treatment campaigns. Next, one or two volunteer teachers and one community health worker were trained per village for drug administration. Praziquantel was administered by trained teachers to children with help of the community health workers for the non-enrolled school-age children. Treatment was offered free of charge, with dosing according to WHO guidelines [4]. The coverage rate was calculated by dividing the total number of school-age children treated, regardless of whether they were enrolled or not, by the total number of school-age children in the village, estimated from the total population of each village.

Statistical analysis

Demographic and laboratory data from the baseline survey were double entered into an Excel spreadsheet (Microsoft Corporation; Redmond, United States of America), and cross-checked with EpiInfo version 3.2 (Centers for Disease Control and Prevention; Atlanta, United States of America). Smartphones were used to directly enter data of all the follow-up surveys. These databases were uploaded and maintained on a central server (Open Data Kit) in Atlanta. A child was considered infected when there was at least one S. mansoni egg detected on one of the Kato-Katz thick smears. Village level prevalence and study arm level prevalence values were calculated. Reduction in the prevalence of S. mansoni infection by study arm was calculated using the following formula: prevalence reduction rate = [(prevalence at final survey—prevalence at baseline) / prevalence at baseline] × 100. As not all of the children could provide the three intended stool samples, intensity of infection was determined in eggs per gram of stool (EPG) taking into account the number of samples provided per participant and the fact that each slide contained 41.7 mg of stool. The total number of eggs counted on all the slides of each participant was thus multiplied by a factor of 12, 6, or 4 depending on whether the child provided duplicate, quadruplicate or sextuplicate Kato-Katz thick smears, respectively. Species-specific helminth egg counts were truncated at 1,000 EPG. Children infected with S. mansoni were classified as light (<100 EPG), moderate (100–399 EPG), and heavy infection (≥400 EPG), according to WHO thresholds.
The arithmetic mean (AM) of infection intensity was evaluated at individual level, excluding negative children, and at village-level, including negative children; both expressed as EPG. The reduction rate in intensity of infection was calculated as follows: egg reduction rate (ERR) = (AM EPG at village level at baseline—AM EPG at village level in the final survey) / AM EPG at village level at baseline x 100. The primary analysis estimated differences between the arms in the final year. Differences in prevalence were assessed using generalized estimating equations (GEE) for binary distributed outcomes with logit link and independent correlation structure to account for potential correlations within village clusters. The adjusted analysis used the same model but included baseline prevalence, sex, and age as additional covariates. Additionally, the adjusted model was weighted to account for the fact that in some villages less than 100 school-age children were sampled. Differences in *S. mansoni* egg counts were assessed using GEE for negative binomial distributed outcomes with log link and independent correlation structure. Adjusted and unadjusted models were estimated in the same way as the prevalence models. The same GEE models were also performed by sex to explore the effect of gender on the difference between intervention arms. The primary analysis was done in SAS version 9.4 (SAS Institute Inc.; Cary, United States of America). Details on sample size considerations have been published elsewhere [9]. The statistical analysis plan can be found here [21].

**Results**

**Study flow**

Parasitologic surveys, interventions, and assessments took place between March 2012 and March 2016. In the first year (2012), 7,500 children aged 9–12 years were randomly selected in the 75 participating schools. Ninety children were missed because of refusal or absence. Hence, 7,410 children were included in the baseline cross-sectional survey consisting of 40.2% of girls with an average age of 10.5 years. The mean number of participants per school was 99.6 in arm 1, 98.6 in arm 2, and 98.2 in arm 3. For the final survey in 2016, again, 7,500 children aged 9–12 years were targeted. Overall, 277 children missed this assessment, resulting in 7,223 children participating. There were 44.0% girls (Fig 2) and the average age was 10.1 years.

In addition, 4,812 first-grade children, aged 5–8 years, were surveyed at baseline and 4,513 in the final survey. The proportion of girls in this age group was 43.2% with an average age of 6.5 years in 2012 and 47.6% with an average age of 6.4 years in 2016.

**Coverage rate of preventive chemotherapy**

Preventive chemotherapy was offered only to school-age children. In the first year, coverage of preventive chemotherapy was relatively low in the three arms with 64.2%, 64.4%, and 47.9% in arms 1, 2, and 3, respectively. In subsequent years, the average coverage rate increase to at least 74% in all arms (Table 1). It was observed that in many localities, the coverage rate was below the WHO recommended level of 75%, which was also aimed by the SCORE study protocol [4].

**Differences in prevalence and intensity of *S. mansoni* infection in children aged 9–12 years**

The overall *S. mansoni* prevalence at baseline was 20.9%. The baseline prevalence in the three treatment arms ranged from 17.4% to 25.2% (Table 2). The final survey showed an overall prevalence of 15.3% in the whole study area among children aged 9–12 years with the lowest prevalence observed in arm 1 (10.4%). However, the estimate was not statistically significantly different from the 18.2% observed in arm 2 (odds ratio (OR) = 0.52, 95% confidence interval
A similar trend was observed for the difference between arms 1 and 3 (10.4% vs. 17.3%; OR = 0.55, 95% CI = 0.23–1.29). There was also no significant difference between arms 2 and 3 (OR = 1.06, 95% CI = 0.64–1.75) (Table 3). Decreases in prevalence were observed in 22 of 25 schools of arm 1; however, a village named Bié was characterized as a “persistent hotspot”, where prevalence continued to increase, reaching 91.8% by the study end, despite annual treatment over four years (Fig 3A). A decrease was also observed in 15 and 19 schools in arms 2 and 3, respectively.

The mean infection intensity by arm at baseline (including egg-negative children) were 12.4 EPG, 17.4 EPG, and 20.1 EPG in arms 1, 2, and 3, respectively. Similarly to the prevalence, infection intensity was lowest in arm 1 in the final year with a mean $S. mansoni$ egg count of

![Study profile and number of schools with 9- to 12-year-old participants in each arm. Arm 1: praziquantel treatment every year; Arm 2: praziquantel treatment only in the first two years, followed by two years without treatment; Arm 3: praziquantel treatment every other year without treatment in-between.](https://doi.org/10.1371/journal.pntd.0008845.g002)

(CI) = 0.23–1.16). A similar trend was observed for the difference between arms 1 and 3 (10.4% vs. 17.3%; OR = 0.55, 95% CI = 0.23–1.29). There was also no significant difference between arms 2 and 3 (OR = 1.06, 95% CI = 0.64–1.75) (Table 3). Decreases in prevalence were observed in 22 of 25 schools of arm 1; however, a village named Bié was characterized as a “persistent hotspot”, where prevalence continued to increase, reaching 91.8% by the study end, despite annual treatment over four years (Fig 3A). A decrease was also observed in 15 and 19 schools in arms 2 and 3, respectively.

The mean infection intensity by arm at baseline (including egg-negative children) were 12.4 EPG, 17.4 EPG, and 20.1 EPG in arms 1, 2, and 3, respectively. Similarly to the prevalence, infection intensity was lowest in arm 1 in the final year with a mean $S. mansoni$ egg count of

### Table 1. Coverage of preventive chemotherapy with praziquantel in school-age children by study arm over the four year of intervention in a cluster-randomized trial in Côte d’Ivoire.

| Treatment   | Study arm | School-age children treated | School-age children total number | % of school-age children treated |
|-------------|-----------|-----------------------------|---------------------------------|---------------------------------|
| Year 1 (2012) | 1         | 8,358                       | 13,010                          | 64.2                            |
|             | 2         | 11,548                      | 17,937                          | 64.4                            |
|             | 3         | 6,898                       | 14,413                          | 47.9                            |
| Year 2 (2013) | 1         | 10,246                      | 13,755                          | 74.4                            |
|             | 2         | 15,504                      | 18,534                          | 83.6                            |
| Year 3 (2014) | 1         | 13,239                      | 14,231                          | 93.0                            |
|             | 3         | 12,057                      | 16,232                          | 74.9                            |
| Year 4 (2015) | 1         | 14,206                      | 15,778                          | 90.0                            |

![Coverage of preventive chemotherapy with praziquantel in school-age children by study arm over the four year of intervention in a cluster-randomized trial in Côte d’Ivoire. Arm 1: praziquantel treatment every year; Arm 2: praziquantel treatment only in the first two years, followed by two years without treatment; Arm 3: praziquantel treatment every other year without treatment in-between.](https://doi.org/10.1371/journal.pntd.0008845.t001)
7.9 EPG compared with 11.5 EPG in arm 2 and 15.4 EPG in arm 3 (Table 4). However, also in this case, the CIs were large and included unity (Table 3). Adjusting for baseline prevalence, age, and sex did not noteworthy change the estimates. The variation in this AM intensity of infection per school per arm showed an almost continuous decline over time in arms 1 and 2. However, in arm 3, a rapid increase in this mean intensity of infection was observed (Fig 3B).

In the final survey, it was noted that the proportion of heavy infections (≥400 EPG) decreased from 0.8% to 0.2% in arm 1 and from 1.2% to 0.6% in arm 2, but remained stable in arm 3 (1.0%) (Fig 4). No significant differences related to sex were observed in the study outcomes.

**Differences in prevalence and intensity of *S. mansoni* infection among first-grade children**

A total of 4,812 first-grade children entering school (before receiving preventive chemotherapy) participated in the baseline survey, of whom 257 (5.3%) were infected with *S. mansoni*. At the final survey, among the 4,513 participating first-grade children, the prevalence decreased

| Arm | Baseline (2012) | Final survey (2016) | Absolute change | Relative change (%) |
|-----|-----------------|---------------------|-----------------|---------------------|
|     | Examined | Infected | Prevalence (%) | Examined | Infected | Prevalence (%) |         |         |
| 1   | Male  | 1,463  | 284  | 19.4  | 1,333  | 148  | 11.1  | -8.3  | -42.8 |
|     | Female | 1,027  | 151  | 14.7  | 1,097  | 104  | 9.5   | -5.2  | -35.4 |
|     | Overall | 2,490  | 435  | 17.5  | 2,430  | 252  | 10.4  | -7.0  | -40.2 |
| 2   | Male  | 1,462  | 328  | 22.4  | 1,355  | 266  | 19.6  | -2.8  | -12.5 |
|     | Female | 1,003  | 171  | 17.0  | 1,011  | 164  | 16.2  | -0.8  | -4.7  |
|     | Overall | 2,465  | 499  | 20.2  | 2,366  | 430  | 18.2  | -2.0  | -9.9  |
| 3   | Male  | 1,505  | 406  | 29.9  | 1,355  | 261  | 19.3  | -7.6  | -28.2 |
|     | Female | 950    | 212  | 22.3  | 1,072  | 159  | 14.8  | -7.5  | -33.6 |
|     | Overall | 2,455  | 618  | 25.2  | 2,427  | 420  | 17.3  | -7.9  | -31.4 |

Table 3. Comparison of prevalence and intensity of *S. mansoni* infection between arms at the final survey (2016) in a cluster-randomized trial in Côte d'Ivoire. Adjustment of OR and CR are for age, sex, and baseline prevalence. Arm 1: praziquantel treatment every year; Arm 2: praziquantel treatment only in the first two years, followed by two years without treatment; Arm 3: praziquantel treatment every other year without treatment in-between.

| Age group | Arms compared | Prevalence | Intensity |
|-----------|---------------|------------|-----------|
|           | Unadjusted prevalence model estimate OR (95% CI) | Adjusted prevalence model estimate OR (95% CI) | P | Unadjusted intensity model estimate CR (95% CI) | Adjusted intensity model estimate CR (95% CI) | P |
| Arm 1 vs arm 2 | 0.52 (0.23–1.16) | 0.11 | 0.56 (0.25–1.24) | 0.15 | 0.68 (0.20–2.34) | 0.55 | 0.52 (0.18–1.53) | 0.23 |
| 9–12 years | Arm 1 vs arm 3 | 0.55 (0.24–1.30) | 0.17 | 0.72 (0.24–2.14) | 0.56 | 0.51 (0.15–1.77) | 0.29 | 0.39 (0.08–1.93) | 0.25 |
| Arm 2 vs arm 3 | 1.06 (0.64–1.75) | 0.81 | 1.30 (0.68–2.48) | 0.43 | 0.75 (0.44–1.25) | 0.27 | 0.75 (0.28–2.01) | 0.57 |
| Arm 1 vs arm 2 | 0.83 (0.23–2.97) | 0.77 | 0.80 (0.30–2.11) | 0.65 | 0.64 (0.14–2.97) | 0.57 | 0.62 (0.13–3–03) | 0.56 |
| 5–8 years | Arm 1 vs arm 3 | 0.47 (0.13–1.72) | 0.25 | 0.73 (0.19–2.82) | 0.65 | 0.37 (0.08–1.71) | 0.20 | 0.40 (0.08–1.97) | 0.26 |
| Arm 2 vs arm 3 | 0.57 (0.31–1.05) | 0.07 | 0.92 (0.44–1.89) | 0.81 | 0.58 (0.23–1.42) | 0.23 | 0.65 (0.29–1.45) | 0.29 |

CI: confidence interval; CR: count ratio; OR: odds ratio

https://doi.org/10.1371/journal.pntd.0008845.t003
slightly from 4.5% to 3.6% in arm 1 and from 4.7% to 4.3% in arm 2, but slightly increased in arm 3 from 6.8% to 7.9%. Means of infection intensity at village level also varied in the same order across study arms (Table 5). In this age group, no significant difference was observed

**Fig 3. Dynamique of prevalence and infection intensity of *S. mansoni* in a 5-year cluster randomized trial among 9- to 12-year-old children in Côte d’Ivoire, stratified by intervention arm.** (A): Variation of *S. mansoni* prevalence among children aged 9–12 years over time per village and by arm. Each line represents a village and black line represents the overall prevalence of the arm. (B): Variation of arithmetic mean intensity of *S. mansoni* per village over year by arm. Each line represents a village and black line represents the overall prevalence of the arm. Arm 1: praziquantel treatment every year; Arm 2: praziquantel treatment only in the first two years, followed by two years without treatment; Arm 3: praziquantel treatment every other year without treatment in-between.

https://doi.org/10.1371/journal.pntd.0008845.g003

Table 4. *Schistosoma mansoni* intensity changes between baseline (2012) and final survey (2016) among 9- to 12-year-old children in three arms of a cluster-randomized trial in Côte d’Ivoire. Arm 1: praziquantel treatment every year; Arm 2: praziquantel treatment only in the first two years, followed by two years without treatment; Arm 3: praziquantel treatment every other year without treatment in-between.

| Arm | Baseline (2012) | Final survey (2016) | Egg reduction rate |
|-----|----------------|-------------------|--------------------|
|     | Individual-level AM infection | Village-level AM infection | Individual-level AM infection | Village-level AM infection |
| 1   | Male           | 77.1              | 15.2               | 89.8              | 9.8               | 35.5% |
|     | Female         | 59.8              | 8.7                | 58.0              | 5.6               | 35.7% |
|     | Overall        | 71.1              | 12.4               | 76.7              | 7.9               | 36.0% |
| 2   | Male           | 108.1             | 24.5               | 72.1              | 14.5              | 41.0% |
|     | Female         | 49.7              | 7.9                | 50.5              | 8.1               | -2.0% |
|     | Overall        | 88.1              | 17.4               | 63.8              | 11.5              | 33.8% |
| 3   | Male           | 88.1              | 23.5               | 97.7              | 18.8              | 20.0% |
|     | Female         | 66.9              | 14.7               | 77.0              | 11.2              | 24.1% |
|     | Overall        | 80.8              | 20.1               | 89.9              | 15.4              | 23.1% |

AM: arithmetic mean; EPG: eggs per gram of stool; **Individual-level AM infection**: excluding negative children expressed as EPG; **Village-level AM infection**: including negative children expressed as EPG

https://doi.org/10.1371/journal.pntd.0008845.t004
between the study arms in reduction of prevalence and infection intensity at the study end (Table 3).

Discussion

Preventive chemotherapy with praziquantel is the key strategy for morbidity control of schistosomiasis, as recommended by WHO and implemented by national control programs [6]. National control programs need reliable data to monitor the effectiveness of currently recommended policies, in order to refine and enhance strategies should drug interventions fail. The current recommendation for preventive chemotherapy with praziquantel in moderate endemicity areas is to treat school-age children once every other year [22]. In our study, in addition to this recommended approach, we also tested two additional treatment schedules: annual treatment and treatment on two consecutive years, followed by two years without treatment in-between.

Table 5. Prevalence and intensity of S. mansoni infection among 5- to 8-year-old children for baseline (2012) and final survey (2016) in a cluster-randomized trial in Côte d’Ivoire. Arm 1: praziquantel treatment every year; Arm 2: praziquantel treatment only in the first two years, followed by two years without treatment; Arm 3: praziquantel treatment every other year without treatment in-between.

| Study year        | Study arm | Number tested | Number infected | Prevalence (%) | Heavily infected (%) | Individual-level AM infection | Village-level AM infection |
|-------------------|-----------|---------------|-----------------|----------------|----------------------|-------------------------------|---------------------------|
| Baseline (2012)   | 1         | 1,409         | 63              | 4.5            | 9 (0.6)              | 165.9                        | 8.2                       |
|                   | 2         | 1,750         | 82              | 4.7            | 9 (0.5)              | 143.7                        | 5.8                       |
|                   | 3         | 1,653         | 112             | 6.8            | 9 (0.5)              | 129.7                        | 8.6                       |
|                   | Total     | 4,812         | 257             | 5.3            | 27 (0.6)             | 146.4                        | 7.5                       |
| Final survey      | 1         | 1,442         | 52              | 3.6            | 1 (0.1)              | 83.6                         | 2.8                       |
| (2016)            | 2         | 1,499         | 65              | 4.3            | 5 (0.3)              | 108.6                        | 4.7                       |
|                   | 3         | 1,572         | 116             | 7.4            | 10 (0.6)             | 110.8                        | 7.4                       |
|                   | Total     | 4,513         | 233             | 5.2            | 16 (0.4)             | 101.0                        | 4.9                       |

AM: arithmetic mean; Individual-level AM infection: excluding negative children expressed as EPG; Village-level AM infection: including negative children expressed as EPG; EPG: eggs per gram of stool.
treatment. The effectiveness of the treatment strategy was evaluated by key indicators, including the prevalence and intensity of *S. mansoni* infection in the targeted group (children aged 9–12 years) and among first-grade children (aged 5–8 years) entering school. Our study compared the three treatment strategies by monitoring these primary outcomes over a 5-year period. As expected, data confirmed that the three treatment strategies all yielded reductions in the overall prevalence of *S. mansoni* infection in school-age children. However, in the final survey, no statistically significant difference in prevalence and intensity of *S. mansoni* infection was observed between study arms. Our results corroborate findings from other SCORE studies conducted elsewhere in sub-Saharan Africa [10,11,23,24]. Additionally, there was no significant difference in prevalence and intensity of infection between study arms at the final survey among first-grade children who have never been treated before, suggesting a similar impact on the *S. mansoni* transmission in the community regardless of the treatment schedule.

Despite the reductions in prevalence observed at the study end, all the study arms remained in the moderate endemicity category, as defined by WHO (prevalence between 10% and 49%) and several cases of heavy intensity infections have been observed even among children aged 5–8 years. Hence, it seems difficult that a control program emphasizing preventive chemotherapy alone will reach the goal of eliminating schistosomiasis as a public health problem.

There was one village, Biélé, which is considered as a persistent hotspot [25–27] where the force of transmission was apparently very high, heavily influencing the overall prevalence in arm 1. Despite the fact that coverage of preventive chemotherapy in this village increased over the four years of intervention to reach 75% in the final year, the prevalence increased gradually up to a very high level (92%) at the end of the study. In such settings, extending preventive chemotherapy to the whole population, increasing the frequency of treatments, or supplementing other interventions (e.g., snail control and behavioral changes to reduce human-water contact) as previously suggested [28–30], are warranted.

The relatively low coverage for preventive chemotherapy compared to the standard recommended by WHO, observed in the three study arms during the first year was, at least partially, explained by a post-election crisis, which affected the stability of the education system and community cohesion in the area, and limited our efforts for population sensitization [31]. This was the main limitation of the study. Following significant improvements in the political situation after 2013, the school-based treatment achieved an average coverage rate of at least 74% in all arms in subsequent years. This rate is close to the minimal target (75%) recommended by WHO [22] and the SCORE protocol and should instead contribute to further reduce prevalence and intensity. Taking into account the fact that the coverage targeted could not be reached in several villages of the study and that treatment coverage was an intermediate variable on the causal path between treatment and prevalence, we did not include coverage in the model as done for another SCORE study [11]. However, high treatment coverage rates from the first year of intervention could have resulted in better reduction of prevalence and intensity of *S. mansoni* in the study arms.

In conclusion, our results showed that the three school-based treatment strategies with praziquantel investigated, achieved reduction in prevalence and intensity of *S. mansoni* infection among children aged 9–12 years. At the end of the study, no statistically significant differences were observed between the study arms. However, it is important to put our results in context with findings derived from three sister trials conducted simultaneously in other countries, before final recommendations can be drawn. In view of the relatively modest reductions in prevalence and infection intensity observed in all the three study arms, preventive chemotherapy alone was insufficient to consider the ultimate goal of schistosomiasis elimination [12].
Acknowledgments

The authors thank the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) secretariat (Daniel G. Colley, Carl Campbell Jr., Charles H. King, and Sue Binder), Méité Abdoulaye and his team from the “Programme National de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive” in Côte d’Ivoire. We also thank the laboratory technicians who contributed to this work.

Author Contributions

Conceptualization: Mamadou Ouattara, Patrick K. Yao, Jean T. Coulibaly, Jürg Utzinger, Eliézer K. N’Goran.

Data curation: Mamadou Ouattara, Patrick K. Yao, Eliézer K. N’Goran.

Formal analysis: Jan Hattendorf.

Investigation: Mamadou Ouattara, Nana R. Diakité, Jean T. Coulibaly, Rufin K. Assaré, Fidèle K. Bassa, Naférime Koné, Négonorogo Guindo-Coulibaly, Jürg Utzinger.

Methodology: Mamadou Ouattara, Nana R. Diakité, Eliézer K. N’Goran.

Project administration: Mamadou Ouattara, Jürg Utzinger, Eliézer K. N’Goran.

Supervision: Mamadou Ouattara, Jürg Utzinger, Eliézer K. N’Goran.

Writing – original draft: Mamadou Ouattara, Nana R. Diakité.

Writing – review & editing: Mamadou Ouattara, Nana R. Diakité, Patrick K. Yao, Jasmina Saric, Jean T. Coulibaly, Rufin K. Assaré, Fidèle K. Bassa, Naférime Koné, Négonorogo Guindo-Coulibaly, Jan Hattendorf, Jürg Utzinger, Eliézer K. N’Goran.

References

1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014; 383: 2253–2264. https://doi.org/10.1016/S0140-6736(13)61949-2 PMID: 24698483

2. Lai YS, Biedermann P, Ekpo UF, Garba A, Mathieu E, Midzi N et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. Lancet Infect Dis. 2015; 15: 927–940. https://doi.org/10.1016/S1473-3099(15)00066-3 PMID: 26004859

3. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat Rev Dis Primers. 2018; 4:13. https://doi.org/10.1038/s41572-018-0013-8 PMID: 30093684

4. WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. World Health Organ Tech Rep Ser. 2002; 912: 1–57.

5. WHO. A roadmap for implementation: accelerating work to overcome the global impact of neglected tropical diseases. Geneva: World Health Organization, 2012.

6. WHO. Schistosomiasis and soil-transmitted helminthiasis: number of people treated in 2016. Wkly Epidemiol Rec. 2017; 92:49–60. PMID: 29218962

7. Colley DG. Morbidity control of schistosomiasis by mass drug administration: how can we do it best and what will it take to move on to elimination? Trop Med Health. 2014; 42: 25–32.

8. Ezeamama AE, He CL, Shen Y, Yin XP, Binder SC, Campbell CH, et al. Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries. BMC Infect Dis. 2016; 16:229. https://doi.org/10.1186/s12879-016-1575-2 PMID: 27230666

9. Assaré RK, Knopp S, N’Guessan NA, Yapi A, Tian-Bi YNT, Yao PK et al. Sustaining control of schistosomiasis mansoni in moderate endemicity areas in western Côte d’Ivoire: a SCORE study protocol. BMC Public Health. 2014; 14:1290. https://doi.org/10.1186/1471-2458-14-1290 PMID: 25519880

10. Olsen A, Kinung’hi S, Magnusson P. Comparison of the impact of different mass drug administration strategies on infection with Schistosoma mansoni in Mwanza region, Tanzania—a cluster-randomized controlled trial. Am J Trop Med Hyg. 2018; 99:1575–1579. https://doi.org/10.4269/ajtmh.18-0671 PMID: 30390779
11. Phillips AE, Gazzinelli-Guimaraes PH, Aurelio HO, Ferro J, Nala R, Clements M et al. Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: a SCORE project in northern Mozambique. PLoS Negl Trop Dis. 2017; 11: e0006061. https://doi.org/10.1371/journal.pntd.0006061 PMID: 29220347

12. Knopp S, Person B, Ame SM, Ali SM, Muhsin J, Juma S et al. Evaluation of integrated interventions layered on mass drug administration for urogenital schistosomiasis elimination: a cluster-randomised trial. Lancet Glob Health. 2019; 7: e1118–1129. https://doi.org/10.1016/S2214-109X(19)30189-5 PMID: 31255591

13. Raso G, Utzinger J, Silué KD, Ouattara M, Yapi A, Toty A et al. Disparities in parasitic infections, perceived ill health and access to health care among poorer and less poor schoolchildren of rural Côte d’Ivoire. Trop Med Int Health. 2005; 10:42–57. https://doi.org/10.1111/j.1365-3156.2004.01352.x PMID: 15655013

14. Fürst T, Raso G, Acka CA, Tschanzen AB, N’Goran EK, Utzinger J. Dynamics of socioeconomic risk factors for neglected tropical diseases and malaria in an armed conflict. PLoS Negl Trop Dis. 2008; 3: e513. https://doi.org/10.1371/journal.pntd.0000513 PMID: 19907632

15. Acka CA, Raso G, N’Goran EK, Tschanzen AB, Bogoch II, Seraphin E et al. Parasitic worms: knowledge, attitudes, and practices in western Côte d’Ivoire with implications for integrated control. PLoS Negl Trop Dis. 2010; 4: e810. https://doi.org/10.1371/journal.pntd.0000891 PMID: 21200423

16. Asssaré RK, Hürlimann E, Ouattara M, N’Guessna NA, Tian-Bi Y-NT, Yapi A et al. Sustaining the control of Schistosoma mansoni in western Côte d’Ivoire: baseline findings before the implementation of a randomised trial. Am J Trop Med Hyg. 2016; 94: 352–360. https://doi.org/10.4269/ajtmh.15-0530 PMID: 26598571

17. Asssaré RK, Tian-Bi Y-NT, Yao PK, N’Guessna NA, Ouattara M, Yapi A et al. Sustaining control of schistosomiasis mansoni in western Côte d’Ivoire: results from a SCORE study, one year after initial praziquantel administration. PLoS Negl Trop Dis. 2016; 10: e0004329. https://doi.org/10.1371/journal.pntd.0004329 PMID: 26789749

18. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. Clin Microbiol Infect. 2015; 21:529–542. https://doi.org/10.1016/j.cmi.2015.03.014 PMID: 25843503

19. Knopp S, Speich B, Tattendorff J, Rinaldi L, Mohammed KA, Khamis IS et al. Diagnostic accuracy of Kato-Katz technique: experience from three randomised controlled trials. Parasit Vectors. 2015; 8: 82. https://doi.org/10.1186/s13071-015-0702-z PMID: 25652120

20. King CH, Kittur N, Binder S, Campbell CH Jr, N’Goran EK, Meite A, et al. Impact of different mass drug administration strategies for gaining and sustaining control of Schistosoma mansoni and Schistosoma haematobium infection in Africa. Am J Trop Med Hyg. 2020; 103 (Suppl 1):14–23. https://doi.org/10.4269/ajtmh.19-0829 PMID: 32400356

21. WHO. Schistosomiasis: progress report 2001–2011, strategic plan 2012–2020. Geneva: World Health Organization, 2013. Available from: https://apps.who.int/iris/handle/10665/78074

22. Onkanga IO, Mwinzi PN, Muchiri G, Andiego K, Omedo M, Karanja DMS et al. Impact of two rounds of praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in western Kenya. Int J Parasitol. 2016; 46: 439–445. https://doi.org/10.1016/j.ijpara.2016.01.006 PMID: 26904547

23. Karanja DMS, Awino EK, Wiegand RE, Okoth E, Abudho BO, Mwinzi PN, et al. Cluster randomized trial comparing school-based mass drug administration schedules in areas of western Kenya with moderate initial prevalence of Schistosoma mansoni infections. PLoS Negl Trop Dis. 2017; 11:e0006033. https://doi.org/10.1371/journal.pntd.0006033 PMID: 29059190

24. Kittur N, Binder S, Campbell CH, King CH, Kinung’hi S, Olsen A et al. Defining persistent hotspots: areas that fail to decrease meaningfully in prevalence after multiple years of mass drug administration with praziquantel for control of schistosomiasis. Am J Trop Med Hyg. 2017; 97:1810–1817. https://doi.org/10.4269/ajtmh.17-0368 PMID: 29016344

25. Kittur N, King CH, Campbell CH Jr, Kinung’hi S, Mwinzi PN, Karanja DMS et al. Persistent hot spots in Schistosomiasis Consortium for Operational Research and Evaluation studies for gaining and sustaining control of schistosomiasis after four years of mass drug administration of praziquantel. Am J Trop Med Hyg. 2019; 101: 617–627. https://doi.org/10.4269/ajtmh.19-0193 PMID: 31287046

26. Assaré RK, NTamon RN, Bellai LG, Koffi JA, Mathieu TI, Ouattara M et al. Characteristics of persistent hotspots of Schistosoma mansoni in western Côte d’Ivoire. Parasit Vectors. 2020; 13: 337. https://doi.org/10.1186/s13071-020-04188-x PMID: 32616074
28. Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuente LA, Garba A, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop. 2013; 128: 423–440. https://doi.org/10.1016/j.actatropica.2012.04.013 PMID: 22580511

29. King CH. The evolving schistosomiasis agenda 2007–2017: why we are moving beyond morbidity control toward elimination of transmission. PLoS Negl Trop Dis. 2017; 11: e0005517. https://doi.org/10.1371/journal.pntd.0005517 PMID: 28426653

30. Wiegand RE, Mwinzi PNM, Montgomery SP, Chan YL, Andiego K, Omedo M et al. A persistent hotspot of Schistosoma mansoni infection in a five-year randomized trial of praziquantel preventative chemotherapy strategies. J Infect Dis. 2017; 216: 1425–1433. https://doi.org/10.1093.infdis/jix496 PMID: 28968877

31. Bonfoh B, Raso G, Koné I, Dao D, Girardin O, Cissé G et al. Research in a war zone. Nature. 2011; 474: 569–571. https://doi.org/10.1038/474569a PMID: 21720345